Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

24 Jul 2020 16:58

RNS Number : 0758U
4d Pharma PLC
24 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS 

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

4D PHARMA PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Steven Oliveira and connected parties

City and country of registered office (if applicable)

225 Via Palacio

Palm Beach Gardens

FL 33418

USA

4. Full name of shareholder(s) (if different from 3.)v

Name

South Ocean Capital Management, LLC

Steven Oliveira

South Ocean Capital, LLC

Nemean Asset Management, LLC

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

23/07/2020

6. Date on which issuer notified (DD/MM/YYYY):

24/07/2020

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

13.04

0.00

13.04

131,392,242

Position of previous notification (if

applicable)

12.49

0.00

12.49

131,392,242

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares of £0.0025 each

 

17,127,145

0

13.04

0

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

 

 

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

South Ocean Capital Management LLC

7.61%

 

7.61%

Steven Oliveira

0.62%

 

0.62%

South Ocean LLC

0.47%

 

0.47%

Nemean Asset Management LLC

4.34%

 

4.34%

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

 

11. Additional informationxvi

 

     

 

Place of completion

FL, USA

Date of completion

24 July 2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFLFEEDDISFII
Date   Source Headline
16th Feb 20237:00 amRNSCancellation - 4d Pharma Plc
15th Feb 20231:16 pmRNSCancellation of admission to trading on AIM
2nd Feb 20233:10 pmRNSUpdated Results from Renal Cell Carcinoma Cohort
16th Jan 202310:15 amRNSResult of Meeting
30th Dec 202212:30 pmRNSUpdate on Administration and Suspension of Trading
16th Nov 20227:00 amRNSBlautix Phase II Clinical Trial Results Published
10th Nov 20222:00 pmRNSMRx0518 SITC 2022 poster presentations
5th Oct 20221:00 pmRNSMRx0518 poster presentations at SITC 2022
29th Sep 202210:00 amRNSUpdate on Suspension of Trading on AIM
24th Aug 20227:00 amRNSPublication of preclinical autism research
4th Aug 20223:33 pmRNSPublication of Joint Administrators' Proposals
1st Jul 20225:33 pmRNSTemporary Pause of Recruitment in Clinical Trials
28th Jun 20226:28 pmRNS4D Pharma receives Notice of Delisting from NASDAQ
28th Jun 20223:15 pmRNSResult of AGM
27th Jun 20225:30 pmRNS4D Pharma
24th Jun 20226:22 pmRNSUpdate on Suspension of Trading
24th Jun 202212:30 pmRNSSuspension - 4D Pharma PLC
24th Jun 202212:30 pmRNSTemporary Suspension
14th Jun 20227:00 amRNSPre AGM-Investor Presentation and Q&A
7th Jun 202211:00 amRNSExercise of Options and Total Voting Rights
27th May 20227:00 amRNSASCO 2022 MRx0518 and Bavencio Trial In Progress
25th May 20221:51 pmRNSAnnual Report and Notice of AGM
17th May 20227:00 amRNSATS 2022 - MRx-4DP0004 Phase I/II Part A poster
1st Apr 20227:00 amRNSFinal Results
24th Mar 202210:50 amRNSHolding(s) in Company
23rd Mar 20227:00 amRNSMRx0518 + Keytruda - Primary endpoint met in RCC
21st Mar 202210:46 amRNSHolding(s) in Company
9th Mar 20227:00 amRNSForm F3 Registration Statement filed with SEC
24th Feb 20227:21 amRNSHolding(s) in Company
23rd Feb 20227:00 amRNSParticipation in Chardan Microbiome Summit
22nd Feb 20227:00 amRNSParkinson’s trial receives FDA IND clearance
18th Feb 20227:00 amRNSRestatement of Interim Results to June 30, 2021
27th Jan 20227:00 amRNSAdditional MRx04 Phase 1/2 asthma data and event
25th Jan 20225:17 pmRNSHolding(s) in Company
20th Jan 20227:00 amRNS4D pharma to host virtual KOL event
6th Jan 202210:07 amRNSHolding(s) in Company
5th Jan 20227:00 amRNSParticipation in Upcoming Investor Conference
4th Jan 20227:00 amRNS4D pharma appoints John Doyle as CFO
4th Jan 20227:00 amRNSGrant of Options
13th Dec 20217:00 amRNS4D pharma Phase 1/2 asthma study Part A results
9th Dec 20217:00 amRNS4D pharma presents IBS Phase 2 microbiome analysis
7th Dec 20212:19 pmRNSHolding(s) in Company
19th Nov 20215:58 pmRNSHolding(s) in Company
11th Nov 20217:00 amRNS4D pharma Jefferies Healthcare Conference
12th Oct 20217:00 amRNSJefferies Next Generation IBD Therapeutics Summit
30th Sep 20217:00 amRNSHalf-year Report
16th Sep 20212:08 pmRNSHolding(s) in Company
15th Sep 20217:00 amRNS4D pharma presents two posters at ESMO Congress
9th Sep 20217:00 amRNSParticipation in Upcoming Investor Conferences
19th Aug 20219:44 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.